Prena

Executive Summary

Preterm birth is the leading cause of infant mortality worldwide, affecting over 10% of pregnancies and resulting in significant healthcare costs and long-term disabilities. Current treatments, such as tocolytics and progesterone, have limited efficacy and notable side effects. Prena is developing a novel, non-invasive photobiomodulation device designed to stop and prevent preterm contractions by applying near-infrared light to the uterus. This approach aims to safely modulate uterine activity without systemic pharmacology, potentially offering a superior safety profile and ease of use. The company’s mission is to reduce the number of tragedies associated with preterm birth, addressing a critical unmet need in maternal-fetal health. Founded in 2021 and headquartered in San Francisco, Prena is a privately held early-stage biotechnology company. It has not publicly disclosed funding rounds or valuation, indicating it may still be in preclinical or early clinical development. The technology leverages photobiomodulation, which has established safety in other indications, potentially accelerating the regulatory path. However, key risks include demonstrating efficacy in clinical trials, navigating FDA clearance for a novel device, and scaling manufacturing. If successful, Prena’s platform could transform preterm birth prevention, but the company remains in early development with no publicly available pipeline data.

Upcoming Catalysts (preview)

• Q3 2026Completion of Preclinical Efficacy Studies70% success
• Q2 2026Series A Financing Round60% success
• Q4 2026First-in-Human Clinical Trial Initiation40% success